

➤ What is an informed electrical consent (eConsent)?

The informed electronic consent (eConsent) describes the study and any potential risk or benefits of participation. The study team will answer any questions you may have. By signing the form, you agree to be part of the study, but you may still leave at any time, for any reason, if you change your mind about participating in the future.

➤ Am I required to participate in the LYMPHIR study?

Participating in this study is completely voluntary on your part. Joining this study is your choice. You do not have to take part if you do not want to. If you decide not to join, your regular care will not change. If you join and change your mind later, you can leave the study at any time.

➤ Questions?

To speak to a study representative, contact the LYMPHIR study toll free at 833-610-4660 or email LYMPHIR_SCC@UBC.com.

Hours of Operation: M – F 8:00am – 8:00pm, ET

For more information visit www.lymphirstudy.com or scan the QR code below:



Observational Study of Patients with Cutaneous T-cell Lymphoma (CTCL) treated with LYMPHIR™

Patient Information Pamphlet

➤ About the LYMPHIR study?

This study is evaluating side effects in people living with cutaneous T-cell lymphoma (CTCL) who are receiving treatment with LYMPHIR™. LYMPHIR is a treatment option for patients whose disease has returned (relapsed) or has not responded to prior therapies (refractory). Taking part in this study will not change the care you receive from your doctor. You will not have any extra treatment or medical tests just for the study. The study team will collect information from your usual care, and you may also be asked to complete questionnaires about how you are feeling and how treatment affects your daily life.

➤ Why participate in this study?

CTCL is a rare form of cancer that primarily affects the skin, including sensitive areas such as the skin around the eyes. Because this area is delicate and closely connected to the eyes, the disease can sometimes lead to ocular complications. There is a risk of visual complications with LYMPHIR. These complications may affect eye function and, in some cases, result in vision impairment which may be only temporary.

This study is designed to help doctors better understand why CTCL treatment with LYMPHIR may be causing certain side effects and how long those side effects may last. It looks at how LYMPHIR is used in everyday care, how patients do overtime, and how doctors may improve CTCL treatment with LYMPHIR in the future.

The results may also help healthcare providers better recognize and manage possible eye-related side effects.

➤ Who can join the study?

You may be able to join if you:

- Have been diagnosed with CTCL.
- Have been prescribed LYMPHIR by your doctor, but you have not started treatment yet
- Have had a recent eye exam (within 3 months) before beginning LYMPHIR treatment **OR** are willing to have an eye exam prior to your first dose of LYMPHIR.
- Are able to read and provide informed electronic consent (eConsent)

➤ What will participation involve?

If you join, you will keep getting your usual medical care. There are no extra treatments or tests just for this study. Most of the study information will come from your medical records and from a monthly check-in. You may also be asked to answer questions about your health and quality of life. Your participation in the study may last approximately 1 to 2 years.

➤ Will my privacy be protected?

Yes. Your personal and medical information will be kept private. Information collected during the study will not use your name or other details that directly identify you. You can learn more about privacy in the consent form.